Learn about the implementation of Good Regulatory Practices for pharmaceutical products recommended by the WHO in Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, and Peru.
Learn about the implementation of Good Regulatory Practices for pharmaceutical products recommended by the WHO in Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, and Peru.
To provide guidance on adherence to good regulatory practices for pharmaceutical products, as recommended by the WHO, which contributes to robust regulatory systems backed by an efficient framework of laws, regulations, and guidelines, based on the compilation of experiences from the different actors involved in the field.
This study is based on Annex 11 Good Regulatory Practices in the Regulation of Medical Products of the World Health Organization (WHO).
Measuring Regulatory Performance: A Practitioner’s Guide to Perception Surveys
OCDE: https://www.oecd.org/gov/regulatory-policy/LAC-Brochure-ESP.pdf
The World Health Organization (WHO) has established a comprehensive framework for GMP, outlined in Annex 11 of its Technical Report Series. This framework includes nine fundamental principles that should guide the work of regulatory authorities and are equally applicable in the Latin American context (OMS, 2022):
Learn about them here
Legality: Regulatory systems and the decisions derived from them must have a solid legal basis.
Independence: Institutions responsible for regulating pharmaceutical products must be independent.
Proportionality: Regulation and regulatory decisions must be proportionate to the risk and the regulator's capacity to implement and enforce them.
Clarity: Regulatory requirements must be accessible to and understood by users.
Transparency: Regulatory systems must be transparent, requirements and decisions must be made public, and input on regulatory proposals must be solicited.
Consistency: Regulatory oversight of pharmaceutical products should be consistent with existing government policies and legislation and should be applied in a uniform and predictable manner.
Impartiality: All regulated parties should be treated equitably, fairly, and impartially.
Flexibility: Regulatory oversight should not be prescriptive but flexible in order to respond to a changing environment and unforeseen circumstances. Timely responsiveness to specific needs, particularly public health emergencies, should be built into the regulatory system.
Efficiency: Regulatory systems should achieve their objectives within the required time frame and at reasonable effort and cost. International collaboration promotes efficiency by ensuring the best use of resources.
These principles are essential to ensure that regulatory authorities in Latin America can fulfill their mandate to protect public health while facilitating access to safe and effective medicines.
The enablers of BPR are essential components that create an environment conducive to the effective implementation of regulations in the health sector. These elements range from political support to human and financial resources, quality management systems, and evidence-based decision-making processes. Below are details of these key elements that contribute to the success of a robust and efficient regulatory framework (OMS, 2022):
Learn about them here
Political and whole-of-government support: Sustained support from the highest political and governmental levels, including policymakers, is essential for the successful implementation of the concept and principles of good regulatory practices.
These good practices should be an integral part of all government policies on regulatory systems and have strong political support.
Communication, collaboration, and coordination: Adequate and effective communication plays a key role in the exchange of information within and outside the institutions that make up the regulatory system. When regulatory authorities communicate regularly, both internally and externally, they remain more transparent and accountable. Communicating accurate information prevents potential misunderstandings and the dissemination of misleading information to patients and the public. Communication is a powerful tool for collaboration and coordination with relevant national and international stakeholders, which in turn leads to efficient use of resources and better regulatory outcomes.
Given their responsibilities, regulatory authorities must have adequate staff, infrastructure, and technical tools to perform their tasks. Coordination can be facilitated by communication technologies and the efficient and rapid exchange of information, resulting in fewer gaps and less duplication of effort.
Adequate and sustainable financial resources: Investment in a regulatory system is essential for the proper functioning of a health care system. Having sufficient financial resources to effectively fulfill its regulatory mandate and continuously improve the performance of regulatory activities is essential for the independence, impartiality, consistency, and efficiency of a regulatory system. The financial resources of all institutions in the regulatory system must be sustainable, apart from contributions from donors or philanthropic entities.
Ethics and institutional values: Regulatory staff must comply with the institution's ethical principles and values and demonstrate professionalism. All regulatory staff must be aware of and receive training on the ethical principles and values of the regulatory authority (e.g., a code of conduct). A system must be established, within or outside the regulatory system, to manage deviations from ethics and institutional values.
Robust quality management system: A quality management system, including the application of quality risk management principles, makes regulatory decisions more credible and regulatory operations more stable and consistent. A quality management system contributes to systematic planning, control, and improvement of quality across all regulatory processes and ensures a comprehensive approach.
Science- and data-based decision-making process: Regulatory decisions and decision-making should be based on scientific evidence and accurate data, not intuition or arbitrariness. Science-based decisions lead to consistent and predictable regulatory outcomes. Adherence to international standards and guidelines is a key enabler of science-based regulatory decision-making.
The enabling factors listed above are not effective when present individually. Rather, these factors work in harmony in the application of good regulatory practices. For example, sufficient and sustainable financial resources contribute to the recruitment, development, and retention of competent human resources. Likewise, financial resources must be managed in accordance with good governance practices.
Effective organization and good governance: The structure and chain of authority among all institutions in the regulatory system and within each of them must be well defined. The integrity of the overall regulatory system is fundamental to the efficient performance of each of its constituent institutions.
If more than one institution is involved in the regulatory system, legislation or institutional regulation should provide for clear coordination and no overlap of regulatory activities. Leadership is essential to establishing and realizing the organization's vision, mission, policies, and strategies, which in turn contribute significantly to its efficiency.
Competent human resources: A range of technical and scientific knowledge and skills among regulatory staff contribute to the development, implementation, and maintenance of an effective regulatory system for medical products. Policies and measures for personal and professional development (e.g., training programs, competitive compensation schemes) are essential for regulatory authorities to attract competent staff and retain them in service.
This study is an independent analysis of the adoption of Good Regulatory Practices (GRP) in the regulation of pharmaceutical products in eight (8) Latin American countries. The information comes from reliable sources; however, the data and information described herein are subject to update and validation.
This study is not an assessment of the maturity level of national drug regulatory authorities, nor does it substitute or replace official assessments carried out by authorized bodies such as the World Health Organization (WHO) or the Pan American Health Organization (PAHO).
The findings are based on the information available at the time of preparation and may be subject to change.
The study provides an overview of GMPs in the countries analyzed and seeks to promote regulatory improvements. The authors and the institution assume no responsibility for decisions made based on this study. The documents are protected by copyright and may be used for non-commercial purposes with proper citation. By using these reports, you agree to the terms and conditions set forth in this legal notice and disclaimer.